Movement Alert|DUALITYBIO-B falls 4.34% in Regular Trading, buyback failed to halt continued weakness

Market Focus11-18 09:50

On November 18, DUALITYBIO-B fell 4.34% in Regular Trading, trading at HK$89.3, with turnover of HK$6.40 million.

The clearest disclosed catalyst is continued post-buyback weakness, as the market kept digesting the earlier clinical-data-related disruption despite ongoing company repurchases and chairman share purchases.

Company filings show DUALITYBIO-B disclosed on November 16 that it repurchased 45,400 shares on the Hong Kong Stock Exchange at HK$96.00 to HK$98.95 per share for about HK$4.43 million, with the shares to be held in treasury. This followed multiple buybacks earlier in November and repeated on-market purchases by Chairman Zhu Zhongyuan since late October, including a November 10 purchase at HK$107.276 per share that lifted his stake to 17.66%. Even so, the latest share price has moved below both the recent buyback range and the chairman's accumulation range, indicating near-term support remains limited.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment